Position of the Transparency Council – Tecentriq (atezolizumab)

At its meeting on 22 July 2024,  the Transparency Council adopted position No.  74/2024 on the evaluation of the drug Tecentriq (atezolizumab) for the indication: “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”

Publication of the position >>